Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has scheduled a teleconference with investors and analysts on 23rd October, 2026 to discuss the financial performance for the quarter and half year ended 30th September, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about Credit Rating. India Ratings and Research Private Limited has affirmed the credit rating and revised the outlook from stable to positive of the Company's existing banking facilities, issuer rating, and Non-Convertible Debentures. The rating along with outlook is IND AA+/Positive; and affirmed and assigned the credit rating for the existing and proposed Commercial paper of the Company respectively at IND A1+.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the exchange about an acquisition of 26% stake in Torrent Urja 27 Private Limited, a wholly owned subsidiary of Torrent Green Energy Private Limited, for setting up a captive hybrid (solar + wind) power project in Gujarat.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in securities of the Company by Designated Persons stands closed from 1st October, 2026 and will be re-opened 48 hours after the submission of the Financial Results for the Quarter ended 30th September, 2026 to the Stock Exchanges.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the schedule of investors' meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about a newspaper advertisement regarding a special window for transfer and dematerialization of physical shares.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Postal Ballot, where the shareholders approved the appointment of Shanti Ekambaram as an Independent Director of the Company with 99.98% votes in favor.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet for Investors' Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has received an ESG rating of 70 from NSE Sustainability Ratings and Analytics Limited.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the completion of dispatch of Postal Ballot Notice through electronic mode to its members whose email IDs are registered with the company/depositories as on July 31, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot for the appointment of Shanti Ekambaram as an Independent Director of the Company.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the transcript of a conference call with analysts/investors on financial results for the quarter ended 30th June, 2026, which is available on the company's website.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company, specifically the cessation of Ameera Shah as an Independent Director due to completion of her term.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the link of the recording of the conference call with analysts/investors on financial results for the quarter ended 30th June, 2026, which is available on the company's website.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about change in Management, with Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni ceasing to be part of Senior Management due to change in reporting structure, effective July 30, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 30, 2026, titled 'A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an Annexure B.' The company has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and will publish an extract of the unaudited consolidated financial results. Ameera Shah will be completing her term as an Independent Director of the Company on August 1, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended 30-Jun-26, with the Board approving the results and a limited review report by BS R & Co. LLP. The company also announced that Ameera Shah will be completing her term as an Independent Director on 01-Aug-26.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has appointed Shanti Ekambaram as an Additional Independent Director of the company, effective July 30, 2026, for a term of 3 consecutive years, subject to shareholder approval.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has received final listing and trading approval for 4,19,22,416 new equity shares issued under the scheme of amalgamation with J. B. Chemicals & Pharmaceuticals Limited.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about General Updates - Allotment of 4,19,22,416 fully paid-up Equity shares of the Company to the eligible shareholders of J. B. Chemicals & Pharmaceuticals Limited as on the Record Date i.e. 17th July, 2026, in terms Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders.